Company intelligence / Profile preview

Salvia BioElectronics

Eindhoven, North Brabant, Netherlandssalviabioelectronics.com ↗

Ownership: Private
Employees: ~50
Development stage: Clinical

Overview

The company’s MySalvia Therapy system—a minimally invasive, ultra-thin implant—has received FDA Breakthrough Device Designation and is currently being evaluated in the RECLAIM clinical trial for chronic migraine. Early results are pending; no claims regarding safety or effectiveness have been made as of June 2025.

Therapeutic areas: Neurology
Modalities: DeviceNeuromodulation therapy
Industry: Implantable Medical Devices

Partnerships

No major pharma or biotech partnerships disclosed; supported by leading venture investors.

Beyond the preview

Go deeper on Salvia BioElectronics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Salvia BioElectronics.

Explore the full profile